Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment.

Performance evaluation of the Roche Elecsys® Anti-SARS-CoV-2 immunoassays by comparison with neutralizing antibodies and clinical assessment.

Show other versions (1)

Quantitative measurement of SARS-CoV-2 neutralizing antibodies is highly expected to evaluate immune status, vaccine response, and antiviral therapy. The Elecsys® Anti-SARS-CoV-2 S (Elecsys® anti-S) was developed to measure anti-SARS-CoV-2 S proteins. We sought to investigate whether Elecsys® anti-S...

Full description

Bibliographic Details
Main Authors: Satomi Takei, Tomohiko Ai, Takamasa Yamamoto, Gene Igawa, Takayuki Kanno, Minoru Tobiume, Makoto Hiki, Kaori Saito, Abdullah Khasawneh, Mitsuru Wakita, Shigeki Misawa, Takashi Miida, Atsushi Okuzawa, Tadaki Suzuki, Kazuhisa Takahashi, Toshio Naito, Yoko Tabe
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0274181

Internet

https://doi.org/10.1371/journal.pone.0274181

Similar Items